Logo
Login
$IMRX
$3.83 +$0.12 (3.23%) Close

Company Executives

$IMRX Management Team

Ms. Mallory Morales

Chief Accounting Officer

Treasurer

Age 41
Compensation -
Sex Female

Dr. Brett Hall

Chief Scientific Officer

Age 56
Compensation $1.426M USD
Sex Male

Mr. Harold Brakewood

Chief Business Officer

Age 60
Compensation $1.474M USD
Sex Male

Dr. Igor Matushansky

Chief Medical Officer

Age 52
Compensation -
Sex Male

Mr. Michael Bookman

Chief Legal Officer

Secretary

Age 38
Compensation $1.088M USD
Sex Male

Ms. Ann Berman

Independent Chairman of the Board

Age 72
Compensation $128.7K USD
Sex Female

Dr. Benjamin Zeskind

President

Chief Executive Officer

Co-Founder

Director

Age 43
Compensation $1.945M USD
Sex Male

Ms. Leah Neufeld

Chief People Officer

Age 52
Compensation -
Sex Female

Board of Directors

From the proxy statement filed Apr 20, 2026
Directors
6
serving now
Independent
5 of 5
stated in the proxy; 1 not stated
Average tenure
8.5 years
from year joined
CEO also chairs the board
No
Thomas J. Schall, Ph.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
Peter Feinberg
65 2021
5 years
 Independent
Audit Committee Nominating and Corporate Governance Committee
None stated $103,379
Laurie B. Keating
72 2021
5 years
 Independent None stated PepGen Inc. $106,811
Robert J. Carpenter
81 2009
17 years
 Independent
Compensation Committee
None stated $93,521
Benjamin J. Zeskind, Ph.D.
CEO
 44 2008
18 years
 Not stated None stated None stated Paid as CEO
Diana F. Hausman, M.D.
63 2022
4 years
 Independent None stated None stated $101,521
Thomas J. Schall, Ph.D.
Board chair
 66 2024
2 years
 Independent
Audit Committee
None stated $104,893

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

7 disclosed in the proxy filed Apr 20, 2026
Entities affiliated with Empery Asset Management, LP
Former holders of more than 5% of our Class A common stock
Amount not stated

Purchased 4,015,452 Class A shares and 1,077,764 pre-funded warrants in the August 2025 Private Placement

With us Open in proxy
Merrin Investors LLC
Former holder of more than 5% of our Class A common stock
Amount not stated

Purchased 539,696 Class A shares in the August 2025 Private Placement

With us Open in proxy
Entities affiliated with FMR LLC
Holder of more than 5% of our Class A common stock
Amount not stated

Purchased 7,679,476 Class A shares in the September 2025 Offering

With us Open in proxy
Entities affiliated with HBM Healthcare Investments (Cayman) Ltd.
Holder of more than 5% of our Class A common stock
Amount not stated

Purchased 2,708,559 Class A shares in the September 2025 Offering

With us Open in proxy
Entities affiliated with Empery Asset Management, LP
Former holder of more than 5% of our Class A common stock
Amount not stated

Purchased 541,711 Class A shares in the September 2025 Offering

With us Open in proxy
Ryan (Alex) Peterson
son-in-law of Brett Hall, Ph.D., our Chief Scientific Officer
$129,714
fiscal year 2025

Employed by the Company as Senior Manager, Logistics; received total compensation for fiscal year 2025

Open in proxy
Each of our directors and executive officers
Directors and executive officers of the Company
Amount not stated

Indemnification agreements requiring the Company to indemnify directors and executive officers to the fullest extent permitted by Delaware law

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans